# Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

> **NCT01656161** · PHASE3 · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 120 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Triptorelin embonate 22.5 mg

## Key facts

- **NCT ID:** NCT01656161
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2015-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01656161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01656161, "Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01656161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*